AbbVie, Drug Prices & Medicare Spending

AbbVie manufactures 15 drugs tracked by Medicare Part D with total spending of $16.8B.

Drugs Tracked

$16.8B

Medicare Spending

$311.67

Avg Cost/Claim

80%

Have Generics

AbbVie Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Humira	Adalimumab	$3,414.00	$6.5B	-22.1%	Yes
2	Skyrizi	Risankizumab	$4,475.00	$2.3B	+42.8%	No
3	Rinvoq	Upadacitinib	$3,498.00	$2.3B	+56.3%	No
4	Vraylar	Cariprazine	$383.00	$1.7B	+26.3%	No
5	Mavyret	Glecaprevir/Pibrentasvir	$26,250.00	$945.0M	-21.4%	Yes
6	Linzess	Linaclotide	$180.00	$876.0M	+6.4%	Yes
7	Ubrelvy	Ubrogepant	$305.00	$567.0M	+32.4%	Yes
8	Qulipta	Atogepant	$528.00	$456.0M	+86.4%	Yes
9	Synthroid	Levothyroxine	$14.00	$345.0M	-8.4%	Yes
10	Orilissa	Elagolix	$552.00	$234.0M	-4.8%	Yes
11	Depakote	Divalproex Sodium (brand)	$72.00	$178.0M	-22.4%	Yes
12	Divalproex	Divalproex Sodium	$30.00	$145.0M	-14.2%	Yes
13	Fenofibrate	Fenofibrate	$25.00	$123.0M	-14.2%	Yes
14	Niaspan	Niacin ER	$143.00	$89.0M	-32.4%	Yes
15	Trilipix	Fenofibric Acid	$103.00	$89.0M	-24.6%	Yes

Frequently Asked Questions

AbbVie manufactures 15 drugs tracked by Medicare Part D, with total annual spending of $16.8B.

Mavyret (Glecaprevir/Pibrentasvir) is the most expensive at $26,250.00 per claim.

12 of 15 AbbVie drugs (80%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.